Patents by Inventor Thomas A. Reh

Thomas A. Reh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220193265
    Abstract: Nucleic acid molecules and compositions, and methods using the same are provided herein for intraocular gene-based delivery and expression of two or more proneural bHLH transcription factors in the retina. The nucleic acid molecules, compositions and methods disclosed herein stimulate regeneration of retinal interneurons from retinal Müller glia (MG) and reprogram the MG into bipolar, amacrine, horizontal, and/or ganglion cells. Such methods and nucleic acid molecules are used for vision restoration and/or treatment of a range of ocular diseases involving retinal degeneration after injury, disease, or vison loss.
    Type: Application
    Filed: April 29, 2020
    Publication date: June 23, 2022
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Thomas A. REH, Nikolas L. JORSTAD, Levi TODD
  • Publication number: 20210228741
    Abstract: Methods and compositions are provided for regeneration of retinal neurons and vision restoration after injury, disease, or loss comprising, administration of a nucleic acid sequence encoding Ascl1 and retinal reprogramming potentiating agents, including HDAC inhibitors, STAT-signaling inhibitors and microRNA manipulations in Ascl1-induced retinal regeneration.
    Type: Application
    Filed: April 29, 2019
    Publication date: July 29, 2021
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Thomas A. REH, Nikolas L. JORSTAD, Stefanie G. WOHL
  • Patent number: 10849904
    Abstract: Methods for decreasing rod gene expression in a retina, methods for decreasing the protein products expressed by rod genes in a retina, methods for treating a disease or condition treatable by decreasing rod gene expression or their protein products in a retina, and methods for treating a retinal disease in a subject.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: December 1, 2020
    Assignees: University of Washington, The J. David Gladstone Institutes, a Teatamentary Trust Established Under the Will of J. David. Gladstone
    Inventors: Thomas A. Reh, Paul Nakamura, Sheng Ding
  • Publication number: 20200368234
    Abstract: Methods for decreasing rod gene expression in a retina, methods for decreasing the protein products expressed by rod genes in a retina, methods for treating a disease or condition treatable by decreasing rod gene expression or their protein products in a retina, and methods for treating a retinal disease in a subject using Photoregulin3 (PR3).
    Type: Application
    Filed: August 10, 2018
    Publication date: November 26, 2020
    Applicants: University of Washington, The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J David Gladst
    Inventors: Thomas A. Reh, Paul Nakamura, Andy Shimchuk, Shibing Tang, Sheng Ding
  • Publication number: 20190381047
    Abstract: Methods for decreasing rod gene expression in a retina, methods for decreasing the protein products expressed by rod genes in a retina, methods for treating a disease or condition treatable by decreasing rod gene expression or their protein products in a retina, and methods for treating a retinal disease in a subject.
    Type: Application
    Filed: June 20, 2019
    Publication date: December 19, 2019
    Applicants: University of Washington, The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Glads
    Inventors: Thomas A. Reh, Paul Nakamura, Sheng Ding
  • Patent number: 10363256
    Abstract: Methods for decreasing rod gene expression in a retina, methods for decreasing the protein products expressed by rod genes in a retina, methods for treating a disease or condition treatable by decreasing rod gene expression or their protein products in a retina, and methods for treating a retinal disease in a subject.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: July 30, 2019
    Assignees: University of Washington, The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Gladstone
    Inventors: Thomas A. Reh, Paul Nakamura, Sheng Ding
  • Publication number: 20180125847
    Abstract: Methods for decreasing rod gene expression in a retina, methods for decreasing the protein products expressed by rod genes in a retina, methods for treating a disease or condition treatable by decreasing rod gene expression or their protein products in a retina, and methods for treating a retinal disease in a subject.
    Type: Application
    Filed: March 28, 2016
    Publication date: May 10, 2018
    Applicants: University of Washington, The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Glads
    Inventors: Thomas A. Reh, Paul Nakamura, Sheng Ding
  • Patent number: 8557972
    Abstract: The present invention provides reagents and methods for RNA transfection and protein expression.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: October 15, 2013
    Assignee: University of Washington through its Center for Commercialization
    Inventors: Thomas A. Reh, Olivia M. Bermingham-McDonogh, Toshinori Hayashi
  • Publication number: 20110151557
    Abstract: The present invention provides reagents and methods for RNA transfection and protein expression
    Type: Application
    Filed: December 21, 2010
    Publication date: June 23, 2011
    Applicant: University of Washington
    Inventors: Thomas A. Reh, Olivia M. Bermingham-McDonogh, Toshinori Hayashi
  • Publication number: 20110044957
    Abstract: A cell culture system related to extended in vitro culture of mature neuronal cells and methods for preparing the cell culture system are provided. In a preferred embodiment the invention provides a cell culture system comprising a mixture of mature neuronal retinal cells and cells isolated from a ciliary body. Methods for identifying bioactive agents that alter neurodegeneration of neuronal retinal cells are also provided.
    Type: Application
    Filed: August 23, 2010
    Publication date: February 24, 2011
    Applicant: University of Washington
    Inventors: Ryo KUBOTA, Thomas A. Reh, Andrew J. Fischer
  • Publication number: 20110004272
    Abstract: In one aspect, the invention provides vision prosthesis systems. Exemplary vision prosthesis systems of the invention comprise a light energy generator operably connected to a wearable head piece comprising a device for directing light energy produced by the light energy generator onto a mammalian retina, wherein the light energy generator is tuned to emit light energy of sufficient power to modulate neural activity in the retina. In another aspect, the invention provides methods for irradiating neurons in the retina of the mammalian eye by directing light energy produced by a light energy generator onto a mammalian retina. The methods of the invention may be used to directly modulate the activity of retinal neurons or to introduce molecules into retinal cells.
    Type: Application
    Filed: November 8, 2007
    Publication date: January 6, 2011
    Applicant: WASHINGTON, UNIVERSITY OF
    Inventors: Eric J. Seibel, Thomas A. Reh, Blake Miller
  • Publication number: 20080175826
    Abstract: A cell culture system related to extended in vitro culture of mature neuronal cells and methods for preparing the cell culture system are provided. In a preferred embodiment the invention provides a cell culture system comprising a mixture of mature neuronal retinal cells and cells isolated from a ciliary body. Methods for identifying bioactive agents that alter neurodegeneration of neuronal retinal cells are also provided.
    Type: Application
    Filed: November 16, 2007
    Publication date: July 24, 2008
    Applicant: University of Washington
    Inventors: Ryo Kubota, Thomas A. Reh, Andrew J. Fischer
  • Patent number: 7311723
    Abstract: In one aspect, the invention provides vision prosthesis systems. Exemplary vision prosthesis systems of the invention comprise a light energy generator operably connected to a wearable head piece comprising a device for directing light energy produced by the light energy generator onto a mammalian retina, wherein the light energy generator is tuned to emit light energy of sufficient power to modulate neural activity in the retina. In another aspect, the invention provides methods for irradiating neurons in the retina of the mammalian eye by directing light energy produced by a light energy generator onto a mammalian retina. The methods of the invention may be used to directly modulate the activity of retinal neurons or to introduce molecules into retinal cells.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: December 25, 2007
    Assignee: University of Washington
    Inventors: Eric J. Seibel, Thomas A. Reh, Blake Miller
  • Patent number: 7312025
    Abstract: A cell culture system related to extended in vitro culture of mature neuronal cells and methods for preparing the cell culture system are provided. In a preferred embodiment the invention provides a cell culture system comprising a mixture of mature neuronal retinal cells and cells isolated from a ciliary body. Methods for identifying bioactive agents that alter neurodegeneration of neuronal retinal cells are also provided.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: December 25, 2007
    Assignee: University of Washington
    Inventors: Ryo Kubota, Thomas A Reh, Andrew J Fischer
  • Publication number: 20040147019
    Abstract: A cell culture system related to extended in vitro culture of mature neuronal cells and methods for preparing the cell culture system are provided. In a preferred embodiment the invention provides a cell culture system comprising a mixture of mature neuronal retinal cells and cells isolated from a ciliary body. Methods for identifying bioactive agents that alter neurodegeneration of neuronal retinal cells are also provided.
    Type: Application
    Filed: July 11, 2003
    Publication date: July 29, 2004
    Applicant: University of Washington
    Inventors: Ryo Kubota, Thomas A. Reh, Andrew J. Fischer
  • Patent number: 6750196
    Abstract: In general, the present invention provides methods for promoting the function of retinal cells using neuregulins. A novel aspect of the invention involves the use of neuregulins as growth factors tp promote survival of retinal cells. Treating of the retinal cells to provide these effects may be achieved by contacting retinal cells with a polypeptide described herein. The treatments may be provided to slow or halt net cell loss or to increase the amount or quality of retinal tissue present in the vertebrate.
    Type: Grant
    Filed: March 27, 1995
    Date of Patent: June 15, 2004
    Assignee: Acorda Therapeutics
    Inventors: Thomas A. Reh, Mark A. Marchionni, Kathryn L. McCabe, Olivia Bermingham-McDonogh, Nagesh K. Mahanthappa, David I. Gwynne